A phase 3, open label, randomized study to compare the efficacy and safety of odronextamab (REGN1979), an anti-CD20 x anti-CD3 bispecific antibody, in combination with lenalidomide versus rituximab in combination with lenalidomide in relapsed/refractory participants with follicular lymphoma and marginal zone lymphoma (OLYMPIA-5)

  • Ghanem, Riad (Researcher)
  • Kausche, Lea (Researcher)
  • Klein, Katharina (Researcher)
  • Kovacsova, Judita (Researcher)
  • Krenosz, K. J. (Researcher)
  • Krivic, Denis (Researcher)
  • Kühr, Thomas (Researcher)
  • Lichtenauer, Nina (Researcher)
  • Piringer, Gudrun (Researcher)
  • Popp, Henning Detlef (Researcher)
  • Schneeweiß, Bruno (Researcher)
  • Schwarz, Heike (Researcher)
  • Solomianyi, Oleksii (Researcher)
  • Stegemann, Maike (Researcher)
  • Schmitt, Clemens (PI)

Project: Clinical studies › Clinical Study (Industry project)

Project Details

Description

A phase 3, open label, randomized study to compare the efficacy and safety of odronextamab (REGN1979), an anti-CD20 x anti-CD3 bispecific antibody, in combination with lenalidomide versus rituximab in combination with lenalidomide in relapsed/refractory participants with follicular lymphoma and marginal zone lymphoma (OLYMPIA-5)
StatusActive
Effective start/end date03.07.2024 → 31.12.2027

Fields of science

  • 302024 Haematology
  • 302055 Oncology